ArticleFrontiers in oncology2021

Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.

Jun Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.